Select a medication above to begin.
estradiol
generic
Black Box Warnings .
Endometrial Cancer with Unopposed Estrogen in Patients with Intact Uterus
unopposed estrogen use incr. risk of endometrial CA in patients with intact uterus; adding progestogen has been shown to decr. risk of endometrial hyperplasia, a possible precursor to endometrial CA; perform adequate diagnostic measures (including directed or random endometrial sampling) to rule out malignancy in menopausal patient with abnormal genital bleeding of unknown etiology
Adult Dosing .
Dosage forms: TAB: 0.5 mg, 1 mg, 2 mg
vasomotor symptoms, moderate-severe menopausal
- [1-2 mg PO qd]
- Info: cycle 21 days on, 7 days off; add progestogen x10-14 days/4wk cycle if intact uterus; use lowest effective estrogen dose, shortest effective tx duration
vulvovaginal atrophy, menopausal
- [1-2 mg PO qd]
- Info: cycle 21 days on, 7 days off; add progestogen x10-14 days/4wk cycle if intact uterus; use lowest effective estrogen dose, shortest effective tx duration; not preferred if local symptoms only
osteoporosis prevention, postmenopausal
- [0.5 mg PO qd]
- Info: cycle 21 days on, 7 days off; add progestogen x10-14 days/4wk cycle if intact uterus; weigh estrogen tx risk/benefit
hypoestrogenism
- [2-4 mg PO qd]
- Info: for hypogonadism, oophorectomy, or primary ovarian failure; titrate to lowest effective maintenance dose; add progestogen if intact uterus
metastatic breast CA, palliative tx
- [10 mg PO tid for at least 3mo]
advanced prostate CA, palliative tx
- [1-2 mg PO tid]
transgender hormone therapy, feminizing (off-label)
- [2-6 mg/day PO divided qd-bid]
- Alt: 2-6 mg/day SL divided qd-bid; Info: adjust dose based on patient tx goals, clinical response, and estradiol levels; refer to WPATH or Endocrine Society guidelines
renal dosing
- [see below]
- renal disease: not defined, caution advised
- HD/PD: not defined, caution advised
hepatic dosing
- [see below]
- hepatic impairment: contraindicated
Peds Dosing .
- Dosage forms: TAB: 0.5 mg, 1 mg, 2 mg
puberty induction, female (off-label)
- [associated with hypogonadism, 11 yo and older]
- Dose: 2-4 mg PO qd; Start: 0.25 mg PO qd x6mo, then incr. to 0.5 mg PO qd x6mo, then incr. by 0.5 mg/day PO q6-12mo; Alt: start 5 mcg/kg/dose PO qd, then incr. by 2.5 mcg/kg/day PO q6-12mo; Max: 4 mg/day; Info: add progesterone micronized or medroxyprogesterone after breakthrough bleeding occurs with at least 2y of estrogen tx if intact uterus; after puberty induction, titrate to lowest effective maintenance dose for hypoestrogenism until menopausal age
- [associated with constitutional causes, 13 yo and older]
- Dose: 0.25-0.5 mg PO qd x3-6mo; Alt: 5-10 mcg/kg/dose PO qd x3-6mo; Info: may incr. dose after 6mo if spontaneous puberty progression not achieved; reassess tx need q3-6mo
renal dosing
- [not defined]
- renal impairment: consider adult renal dosing for guidance
- HD/PD: consider adult renal dosing for guidance
hepatic dosing
- [not defined]
- hepatic impairment: consider adult hepatic dosing for guidance